Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Carfilzomib

A second-generation proteasome inhibitor that binds its target irreversibly: approved in the United States in 2012 for relapsed multiple myeloma. This family brings together the active ingredient, labelled standards and other impurities.

Did you know?It derives from epoxomicin, a molecule produced by an actinomycete and described in 1992 as an antitumour agent: in 1999 Craig Crews's laboratory at Yale showed that its target is the proteasome.

CarfilzomibGo to the active ingredient →
CarfilzomibActive ingredientCarfilzomibCat. No. P-C051-001CAS 868540-17-4
Carfilzomib-d8Isotopically labelledCarfilzomib-d8Cat. No. P-C051-002CAS 1537187-53-3

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.